Summary
On April 23, 2026, Acting Attorney General Todd Blanche signed an order moving FDA-approved marijuana products and state-licensed medical-marijuana products to Schedule III of the Controlled Substances Act. The DEA and DOJ also opened an expedited administrative hearing (late June) to consider rescheduling all marijuana from Schedule I to Schedule III. Schedule I status for non-FDA/non-state-licensed marijuana remains. The order follows Trump’s December 2025 executive directive and a near-identical Biden-era rule that never finalized.
Key Points
- The order creates a fast-track federal DEA registration path for state-licensed medical marijuana entities — incorporating state regulatory frameworks into federal scheduling is an administrative innovation, not a statutory change.
- The late-June DEA hearing is the pathway for broader Schedule I→III rescheduling; outcome not yet determined.
- Biden administration moved to reclassify marijuana as Schedule III but the rule never finalized. Trump’s administration is finishing a Biden-era policy direction — rare bipartisan-continuity datapoint.
- Advocate reaction (Adam Smith, Marijuana Policy Project) welcomes the move but frames it as insufficient: “Schedule III stops short of the systemic change we need. It does nothing to end hundreds of thousands of possession arrests each year.”
- Tax implications: rescheduling removes the IRC §280E penalty for state-licensed dispensaries — a material industry financial shift.
- 24 states + DC permit recreational use; 38 states have medical programs. Florida’s 2024 recreational ballot measure failed.
- Trump also signed a psychedelics research EO two days earlier (including ibogaine for PTSD).
Newsletter Angles
- Politics: Clean example of the Trump administration implementing a Biden-initiated policy direction — cuts against pure-reversal narratives and complicates the “everything is culture war” frame.
- Power: The DEA’s administrative-hearing route for broader rescheduling means outcome is determined by career officials, not Congress — policy change without legislation. Parallels concerns in The Anti-CBDC Surveillance State Act about administrative authority.
- Legal: The asymmetric effect (state-licensed medical gets federal integration; recreational stays prohibited) is a federal-state compromise pattern worth tracking independent of outcome.
Entities Mentioned
- Todd Blanche — Acting Attorney General (new entity)
- Donald Trump — December 2025 EO and April 2026 psychedelics EO
- Department of Justice
- DEA, FDA
- Marijuana Policy Project — Adam J. Smith
- Biden administration — prior unsuccessful attempt at same reclassification
Concepts Mentioned
- Controlled Substances Act scheduling
- Administrative hearing as rulemaking channel
- State-federal regulatory integration
- IRC §280E tax implications
Quotes
“The Department of Justice is delivering on President Trump’s promise to expand Americans’ access to medical treatment options.” — Todd Blanche
“Rescheduling cannabis is a historic move towards sanity in cannabis policy… But a move to Schedule III stops short of the systemic change we need. It does nothing to end hundreds of thousands of possession arrests each year.” — Adam J. Smith, MPP
Notes
Blanche as Acting AG is itself worth tracking — permanent AG status remains politically contested. The Schedule III direction has been a bipartisan trajectory; this implements it administratively rather than statutorily.